Characterization of carbapenem-resistant <i>Pseudomonas aeruginosa</i> in Canadian hospitals: 6 years of the CANWARD study (2018–23)
Currently, >20% of clinical isolates of P. aeruginosa in Canada are carbapenem-resistant. Genetic evidence indicates that clonal dissemination of high-risk clones is occurring in Canada. High-risk clones are virulent and often MDR. Continued surveillance of P. aeruginosa is important.
Authors
- Joseph M. Blondeau (ORCID: https://orcid.org/0000-0003-3396-0334)
- George R. Golding (ORCID: https://orcid.org/0000-0002-4285-4747)
- Heather J. Adam (ORCID: https://orcid.org/0000-0002-5646-6454)
- Melanie R. Baxter
- Philippe Lagacé‐Wiens (ORCID: https://orcid.org/0000-0002-5826-2869)
- Andrew Walkty (ORCID: https://orcid.org/0000-0003-2880-2104)
- Melissa McCracken
- George G. Zhanel (ORCID: https://orcid.org/0000-0002-3238-0082)
- James A. Karlowsky (ORCID: https://orcid.org/0009-0004-3330-0285)
Institutions
- Manitoba Health (CA)
- Public Health Agency of Canada (CA)
- Royal University Hospital (CA)
- Health Sciences Centre (CA)
- Shared Health (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1093/jac/dkaf222
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18
Funders
- Pfizer
- University of Manitoba
- Merck Canada
- Sandoz Canada